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Abstract A total of 264 unrelated breast/ovarian cancer
patients and 45 healthy individuals with familial ante-
cedents referred for genetic testing were scanned for
germ-line mutations in BRCA1 and BRCA2 by confor-
mation-sensitive gel electrophoresis (CSGE) and het-
eroduplex analysis by capillary array electrophoresis
(HA-CAE). We detected 101 distinct mutations (41 in
BRCA1 and 60 in BRCA2); ten of them have not
been previously reported. These mutations were
c.2411_2429dup19, c.2802_2805delCAAA and
c.5294A>G (p.E1725E) of BRCA1; and c.667C>T
(p.Q147X), c.2683C>T (p.Q819X), c.5344_5347delA-
ATA, c.5578_5579delAA;insT, c.8260_8261insGA,
c.744+14C>T and c.8099A>G (p.Y2624C) of
BRCA2. Twenty-four diﬀerent mutations, including se-
ven of the new mutations (ﬁve frameshift and two
nonsense), were classiﬁed as pathogenic. These 24
alterations were found in 39 families (12.6% of all
families). A remarkable proportion of deleterious
mutations were found in BRCA2: 25 families carried a
mutation in BRCA2 (BRCA2+; 64.1%) compared with
14 families BRCA1+ (35.9%). The highest incidences of
deleterious mutations were found in families with three
or more cases of site-speciﬁc breast cancer (BC) (27.4%)
and families with BC and ovarian cancer (22.2%).
Finally, four recurrent mutations, 3036_3039delACAA,
c.5374_5377delTATG of BRCA2, as well as c.5272-
1G>A and c.5242C>A (p.A1708E) of BRCA1,
accounted for 44% of all of the deleterious mutations.
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Introduction
Breast cancer (BC) is the most common malignancy
among women in industrialized countries. It is estimated
that 5–10% of all BCs are due to genetic predisposition.
Mutations in the tumor-suppressor genes BRCA1
(MIM#113705) and BRCA2 (MIM#600185) confer an
increased risk of developing BC and ovarian cancer (OC)
(Ford et al. 1998). However, mutations in both genes only
explain approximately 20% of families with evidence of
inherited susceptibility to breast cancer (Wooster and
Weber 2003). Disease-causing mutations are distributed
throughout the entire coding regions of both genes (The
BIC database: http://www.research.nhgri.nih.gov/bic/
Member/index.shtml). Apart from speciﬁc ethnic groups,
there are no predominant mutations accounting for the
majority of inherited breast cancer cases, and deleterious
mutations present signiﬁcant ethnic and geographic var-
iation. Since the identiﬁcation of BRCA1 and BRCA2 as
the principal genes responsible for inherited breast cancer
(Miki et al. 1994; Tavtigian et al. 1996), more than 3,400
distinct DNA sequence variants have been described in
the BIC database, of which 1,723 can be classiﬁed as
pathogenic, including 1,422 truncating mutations (1,064
frameshift and 358 nonsense) and 301 splicing altera-
tions. The remaining mutations, including 1,346 distinct
missense changes, are unclassiﬁed variants of uncertain
clinical consequences.
With a view to oﬀering genetic counseling to BC and
OC patients from Castilla y Leon (Spain), we have
scanned the entire coding regions and the exon–intron
boundaries of BRCA1 and BRCA2. In previous reports
M. Infante Æ M. Dura´n Æ E. Esteban-Carden˜osa
C. Miner Æ E. Velasco (&)
Laboratorio de Gene´tica del Ca´ncer, Instituto de Biologı´a y
Gene´tica Molecular, Universidad de Valladolid,
Sanz y Fore´s s/n, 47003 Valladolid, Spain
E-mail: evelasco@ped.uva.es
Tel.: +34-9831-84809
Fax: +34-9831-84800
E. Esteban-Carden˜osa
Laboratorio de Biologı´a Molecular,
Departamento de Biopatologı´a Clı´nica,
Hospital La Fe´, Valencia, Spain
J Hum Genet (2006) 51:611–617
DOI 10.1007/s10038-006-0404-7
we showed that our BC/OC patients had a wide range of
mutations (Velasco-Sampedro et al. 2002; Duran et al.
2003; Diez et al. 2003). In fact, we had already identiﬁed
a total of 27 novel DNA changes, illustrating the high
diversity of BRCA1/2 mutations in our population
(Velasco-Sampedro et al. 2002; Duran et al. 2003; Ve-
lasco et al. 2005).
Here we present the mutation-detection data corre-
sponding to a set of 309 families analyzed by confor-
mation-sensitive gel electrophoresis (CSGE) and
heteroduplex analysis with capillary array electropho-
resis (HA-CAE), the new high-throughput method
developed by our group (Esteban-Cardenosa et al.
2004). As result of this work, we describe for the ﬁrst
time seven deleterious mutations (two of BRCA1 and
ﬁve of BRCA2), one BRCA2 missense mutation, and
two polymorphic variants (one in each BRCA gene).
Patients and methods
Patients
Ethylenediaminetetraacetic acid (EDTA)-anticoagulated
blood samples as well as written informed consent were
received from 264 unrelated BC/OC patients and 45
healthy individuals with familial antecedents. BC/OC
patients were classiﬁed into groups based on the fol-
lowing criteria:
I. One BC before the age of 40 (67 families)
II. Two BCs in the same family before the age of 50
(33 families)
III. Three or more cases of BC in the same family (62
families)
IV. BC and OC in the same family or patient (27
families)
V. One male BC (14 families)
VI. Bilateral BC (30 families)
VII. Two OCs (no families)
VIII. One BC plus familial aggregation of other types of
cancer (four families)
Additionally, 27 unrelated BC patients of unknown
familial antecedents also participated (no relatives with
BC or OC were available). Finally, 125 relatives of
individuals with deleterious mutations or unclassiﬁed
variants were also studied. DNA from all samples was
extracted using the QIAampDNA Blood mini kit (Qia-
gen, Hilden, Germany).
BRCA1 and BRCA2 mutational analysis
Seventy-three PCR fragments (31 for BRCA1 and 42 for
BRCA2) were ampliﬁed in 23 multiplex PCR groups.
Thermocycling conditions were performed in a Gene-
Amp PCR system 9700 as described before (Esteban-
Cardenosa et al. 2004). The mutation-detection method
was either standard CSGE (92 families) (Ganguly et al.
1993; Cebrian et al. 2002) or ﬂuorescent HA-CAE
(217 families) in an ABI3100 DNA sequencer (Applied
Biosystems) (Esteban-Cardenosa et al. 2004). In this
case, one primer of each pair of the PCR reactions was
ﬂuorescently labeled with FAM, HEX or NED.
DNA sequencing
Fragments showing a CSGE- or HA-CAE-altered pat-
tern were sequenced with the BigDye Terminator
Sequencing Kit v3.1 (Applied Biosystems) with unla-
beled forward and reverse primers.
Mutation nomenclature
Nucleotide positions were numbered considering the
cDNA reference sequences U14680 (BRCA1) and
U43746 (BRCA2). Description of mutations was
according to accepted nomenclature guidelines of the
Human Genome Variation Society (http://www.genomic.
unimelb.edu.au/mdi/mutnomen/).
Results and discussion
Novel mutations
The mutational analysis of BRCA1 and BRCA2 by
CSGE and HA-CAE (Fig. 1) revealed a total of 101
diﬀerent mutations, 41 in BRCA1 and 60 in BRCA2, in
309 families (Tables 1 and 2). Ten novel mutations were
characterized, including ﬁve frameshift (two deletions,
one insertion, one duplication and one combined
deletion/insertion mutation) and two nonsense
mutations (Table 1), as well as one missense, one
synonymous and one intronic variant mutation
(Table 2). These new mutations were c.2802-2805del-
CAAA, c.2411-2429dup19 and c.5294 A>G (p.E1725E)
of BRCA1; and c.667C>T (p.Q147X), c.2683C>T
(p.Q819X), c.5344-5347delAATA, c.5578-5579de-
lAA;insT, c.8260_8261insGA, c.744+14C>T and
c.8099A>G (p.Y2624C) of BRCA2. Together with our
previous results (Velasco-Sampedro et al. 2002; Duran et
al. 2003; Diez et al. 2003; Velasco et al. 2005), novel
mutations represent 29% (37 out of 128 diﬀerent DNA
changes detected in 459 unrelated families) of all muta-
tions identiﬁed, thus illustrating the high variability of
the BRCA genes.
Pathological mutations
Twenty-four diﬀerent disease-causing mutations (9 in
BRCA1 and 15 in BRCA2) were identiﬁed in 39 unre-
lated families (12.6% of all the families), including seven
of the novel mutations, which create premature stop
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codons, truncating the BRCA proteins (Table 1).
Taking into account the previous description of another
four novel truncating mutations (Duran et al. 2003), a
total of 11 diﬀerent new pathogenic mutations have been
exclusively identiﬁed in our patients, indicating that each
population will show a speciﬁc mutational spectrum.
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Heteroduplexes
c.5344_5347delAATA
c.2683C>T (p.Q819X)
Fig. 1 Examples of
heteroduplex analysis by
capillary array electrophoresis
(HA-CAE) patterns. Novel
pathogenic mutations
c.5344_5347delAATA from
BRCA2 exon fragment 11R
labeled with FAM and
c.2683C>T (p.Q819X) from
BRCA2 exon fragment 11D
labeled with NED are shown
(Esteban-Cardenosa et al.
2004). Sizes of DNA standard
Genescan 500-ROX are
indicated
Table 1 Pathogenic mutations of BRCA1 and BRCA2. Novel mutations are marked with an asterisk
Exon Mutation Eﬀect Type of mutation No. of familiesa,b Criteria of patientsc BIC no.
BRCA1
5 c.330A>G 22 bp-deletion Splicing 1 (3) III 1944
5 c.331+1G>A Splicing 1 (2) IV 2843
11 c.2360delC STOP 752 Frameshift 1 (1) IV 2951
11 c.2411-2429dup19* STOP 773 Frameshift 1 (1) III New
11 c.2508-2509delGA STOP 799 Frameshift 1 (1) III 9337
11 c.2802_2805delCAAA* STOP 998 Frameshift 1 (1) III New
11 c.3889_3890delAG STOP 1265 Frameshift 1 (1) H (IV) 2384
18 c.5242C>A p.A1708E Missense
pathogenic
3 (4) VI/ n.d./VI 1147
19 c.5272-1G>A Exon 19 skipping Splicing 4 (5) II/II/III/VI-I 3942
Total 14 (19)
BRCA2
5 c.667C>T* p.Q147X Nonsense 1 (1) III New
11 c.2683C>T* p.Q819X Nonsense 1 (1) IV New
11 c.3036_3039delACAA STOP 958 Frameshift 7 (11) I/III/IV/H (I)/III/n.d./III 1021
11 c.3492insT STOP 1098 Frameshift 1 (2) III 2067
11 c.4150G>T p.E1308X Nonsense 1 (2) I 2480
11 c.5164_5167delGAAA STOP 1668 Frameshift 1 (1) III 2627
11 c.5344_5347delAATA* STOP 1710 Frameshift 2 (2) I / IV New
11 c.5374_5377delTATG STOP 1723 Frameshift 3 (5) H (I)/III/III Duran et al. (2003)
11 c.5578_5579delAA; insT* STOP 1790 Frameshift 1 (1) III New
11 c.6126delT STOP 2003 Frameshift 1 (3) IV Duran et al. (2003)
11 c.6503_6504delTT STOP 2099 Frameshift 1 (1) V 1047
11 c.6884C>G p.S2219X Nonsense 1 (2) II 1054
18 c.8260_8261insGA* STOP 2694 Frameshift 1 (1) H (II) New
23 c.9254_9258delATCAT STOP 3015 Frameshift 2 (2) III/III 1073
25 c.9538_9539delAA STOP 3109 Frameshift 1 (3) III 1422
Total 25 (38)
aIn parenthesis is indicated the number of times the mutation has been identiﬁed in our entire set of breast cancer patients (459 unrelated
patients), including previous studies
bIn previous studies (Velasco-Sampedro et al. 2002; Duran et al. 2003; Diez et al. 2003), we reported seven additional deleterious
mutations that were not found in the present work: c.1135insA (one family), c.3958_3962del5;ins4 (one family), c.5236G>A (p.G1706E)
(one family) and c.5396+1G>A (one family) from BRCA1; and c.1538_1541delAAGA (two families), c.7288C>T (p.Q2354X) (one
family), and c.9476A>T (p.K3083X) (one family) from BRCA2. Therefore, the ﬁnal number of independent families with mutations in
BRCA1 and BRCA2 was 23 and 42, respectively
cSelection criteria I–VIII; see text for deﬁnitions. n.d. No data, H healthy individuals with familial antecedents in parenthesis. One patient
carrying mutation c.5272-1G>A met both criteria I and VI (criterion VI–I)
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Table 2 List of polymorphisms and unclassiﬁed variants of BRCA1 and BRCA2 detected in 309 families. Novel DNA variants are
denoted with an asterisk
DNA change (amino acid change) Exon Frequencya Type of mutation Eﬀectb BIC no. or reference
BRCA1
c.101-115T>C I-1 0.23 Intronic variant Pol. Velasco-Sampedro et al. (2002)
c.233G>A (p.K38K) 3 1 Synonymous Pol. 1317
c.561-34 T>C I-7 0.19 Intronic variant Pol. 1424
c.667-58delT I-8 0.32 Intronic variant Pol. 1322
c.710C>T (p.C197C) 9 0.02 Synonymous Pol. 1237
c.1186A>G (p.Q356R) 11 0.06 Missense Pol. 1014
c.1605C>T (p.R496C) 11 1 Missense U.V. 2294
c.2121C>T (p.L668F) 11 1 Missense U.V. 2313
c.2196G>A (p.D693N) 11 0.05 Missense Pol. 1045
c.2201 C>T (p.S694S) 11 0.22 Synonymous Pol. 1047
c.2430T>C (p.L771L) 11 0.22 Synonymous Pol. 1055
c.2640C>T (p.R841W) 11 1 Missense U.V. 1392
c.2731C>T (p.P871L) 11 0.24 Missense Pol. 1067
c.3232A>G (p.E1038G) 11 0.23 Missense Pol. 1087
c.3238G>A (p.S1040N) 11 8 Missense Pol. 1089
c.3537A>G (p.S1140G) 11 1 Missense U.V. 1790
c.3667A>G (p.K1183R) 11 0.28 Missense Pol. 1099
c.3954G>C (p.A1279P) 11 1 Missense U.V. Velasco et al. (2005)
c.4427T>C (p.S1436S) 13 0.18 Synonymous Pol. 1128
c.4476+45insT I-13 1 Intronic variant Pol. Velasco et al. (2005)
c.4477-10C>T I-13 1 Intronic variant Pol. 2419
c.4604-63C>G I-14 0.18 Intronic variant Pol. 4234
c.4654G>T (p.S1512I) 15 2 Missense Pol. 1136
c.4719G>A (p.V1534M) 15 2 Missense U.V. 1850
c.4956A>G (p.S1613G) 16 0.18 Missense Pol. 1140
c.5075G>A (p.M1652I) 16 2 Missense Pol. 1143
c.5193 +6 C>G I-17 1 Intronic variant U.V. 6643
c.5194-53C>T I-17 0.04 Intronic variant Pol. Velasco-Sampedro et al. (2002)
c.5271+66G>A I-18 0.24 Intronic variant Pol. 1387
c.5294 A>G (p.E1725E)* 19 1 Synonymous Pol. New
c.5396+47dup I-20 3 Intronic variant Pol. 1425
c.5586+35T>A I-23 1 Intronic variant Pol. Velasco et al. (2005)
BRCA2
c.203G>A 2 (5’UTR) 2 0.25 5’UTR Pol. 1666
c.296-7T>A I-2 1 Intronic variant Pol. 2741
c.353 A>G (p.Y42C) 3 1 Missense U.V. 1209
c.451G>C (p.A75P) 3 1 Missense U.V. 1211
c.744+14 C>T* I-6 1 Intronic variant Pol. New
c.744+21A>T I-6 1 Intronic variant Pol. Velasco et al. (2005)
c.744+93C>T I-6 1 Intronic variant Pol. Velasco et al. (2005)
c.745-19 C>T I-6 1 Intronic variant Pol. 2164
c.860-16A>C I-7 1 Intronic variant Pol. 3996
c.909+56C>T I-8 0.02 Intronic variant Pol. 2411
c.1093A>C (p.N289H) 10 0.02 Missense Pol. 1129
c.1155 A>G (p.S309S) 10 1 Synonymous Pol. Velasco et al. (2005)
c.1342C>A (p.H372N) 10 0.23 Missense Pol. 1668
c.1593A>G (p.S455S) 10 2 Synonymous Pol. 1106
c.1991A>G (p.N588S) 10 1 Missense U.V. Velasco et al. (2005)
c.2137+22delT I-10 0.5 Intronic variant Pol. 2416
c.2353C>G (p.L709V) 11 1 Missense U.V. 5192
c.3031G>A (p.D935N) 11 1 Missense U.V. 1255
c.3111G>A (p.Q961Q) 11 1 Synonymous Pol. 1901
c.3199A>G (p.N991D) 11 0.11 Missense Pol. 1903
c.3624A>G (p.K1132K) 11 0.15 Synonymous Pol. 1661
c.4035T>C (p.V1269V) 11 0.06 Synonymous Pol. 1662
c.4296 G>A (p.L1356L) 11 4 Synonymous Pol. 3525
c.4486G>T (p.D1420Y) 11 1 Missense Pol. 1273
c.4926C>T (p.T1566T) 11 2 Synonymous Pol. Velasco et al. (2005)
c.5972C>T (p.T1915M) 11 0.01 Missense Pol. 1108
c.6110G>A (p.S1961N) 11 1 Missense U.V. 6449
c.6328C>T (p.R2034C) 11 4 Missense Pol. 1325
c.7365A>G (p.G2379G) 14 1 Synonymous Pol. Velasco-Sampedro et al. (2002)
c.7470A>G (p.S2414S) 14 0.01 Synonymous Pol. 1125
c.7625 C>T (p.A2466V) 14 1 Missense Pol. 1365
c.7663+53C>T I-14 1 Intronic variant Pol. 2738
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The two new frameshift mutations of BRCA1,
c.2411_2429dup19 and c.2802_2805delCAAA, took
place in exon 11. Both were detected in families with
more than three BC cases (group III). With regard to
BRCA2, the novel two nonsense mutations, p.Q147X
and p.Q819X, and three frameshift mutations,
c.5344_5347delAATA (two families), c.5578_5579de-
lAA;insT and c.8260_8261ins GA, were identiﬁed in
exons 5, 11 and 18. These ﬁve mutations were found in
six unrelated patients of families of criteria groups I, III
(two families), IV (two families), and one healthy indi-
vidual with two familial antecedents with BC
(c.8260_8261ins GA).
BRCA1/BRCA2 ratio of pathogenic mutations
We have found 14 unrelated BRCA1+ families (35.9%)
and 25 BRCA2+ families (64.1%). When taking into
account our previous results (Velasco-Sampedro et al.
2002; Duran et al. 2003; Diez et al. 2003), the ﬁnal
BRCA1/BRCA2 ratio did not change, with 23 and 42
deleterious mutations in BRCA1 (35.4%) and BRCA2
(64.6%), respectively (Table 1). A previous study of the
Spanish Breast Cancer Consortium, which comprised
families from our ﬁrst ﬁve selection criteria (Diez et al.
2003), did not show signiﬁcant diﬀerences between
BRCA1 and BRCA2 (53% BRCA1+ versus 47%
BRCA2+).
Apart from a putative speciﬁc feature of our popu-
lation, there are several alternative reasons for this
BRCA1/BRCA2 imbalance. First, a majority of BRCA2
deleterious mutations (one BRCA1+ versus six
BRCA2+) were reported in young Spanish BC women
from the Mediterranean area (Martinez-Ferrandis et al.
2003). Our data support these results, but only three
pathogenic mutations have been found in group I.
One additional explanation may be an underrepre-
sentation of families with BC and OC, group IV (only
8.7% of our families), where mutations in BRCA1 are
more frequent than in BRCA2 (Risch et al. 2001).
Moreover, a higher incidence of BRCA2 mutations has
been previously reported in Japanese site-speciﬁc BC
families (our group III) (Ikeda et al. 2001). In fact, we
have found 5 BRCA1+ families and 12 BRCA2+
families in group III.
Another cause may be a high frequency of BRCA1
rearrangements, which are undetectable by traditional
PCR-based mutation detection methods such as CSGE
and SSCP. However, this possibility has been recently
excluded, as only three patients carried this sort of
mutations (data not shown).
Finally, another possibility is the absence of the most
prevalent mutation of BRCA1 in Spain, c.187_188de-
lAG of Ashkenazi Jews (Diez et al. 1998, 2003) and the
abundance of recurrent mutations of BRCA2 in our
population. This eﬀect has been previously reported in
Iceland, where a single BRCA2 frameshift mutation,
c.999del5, accounts for 40% of male BCs and 7% of
female BCs (Tulinius et al. 2002). The most prevalent
mutation was c.3036_3039delACAA of BRCA2, which
was found in seven families in this study. In addition, it
was detected in other four families in a preceding report
(Duran et al. 2003), making a total of 11 unrelated
families. This 4-bp deletion is also the most frequent
BRCA2 mutation in Spain (Diez et al. 2003; Salazar et
al. 2005), and it has been detected in many European
countries (Neuhausen et al. 1998). Other important
recurrent mutations of BRCA2 were c.5374_5377del-
TATG, c.6126delT and c.9538_9539delAA (Table 1).
These mutations represent more than one-third of all
pathogenic mutations and may be founder mutations in
our population, although this point has to be corrobo-
rated. Probably, the combination of all these hypotheses
may explain the BRCA1/BRCA2 imbalance of our BC/
OC patients.
The most frequent BRCA1 mutations were c.5272-
1G>A and the missense mutation c.5242C>A
(p.A1708E, Table 1) whose pathogenicity has been
previously demonstrated (Vallon-Christersson et al.
2001). These two alterations are responsible for 39%
of all deleterious mutations of BRCA1. Concerning
Table 2 Continued
DNA change (amino acid change) Exon Frequencya Type of mutation Eﬀectb BIC no. or reference
c.8034-14T>C I-16 0.38 Intronic variant Pol. 1126
c.7987C>T (p.L2587F) 16 1 Missense U.V. Velasco et al. (2005)
c.8099 A>G (p.Y2624C)* 17 1 Missense U.V. NEW
c.8222A>G (p.D2665G) 18 1 Missense U.V. 1382
c.8410G>A (p.V2728I) 18 2 Missense U.V. 1385
c.8559-63_65delGAT I-18 1 Intronic variant Pol. Velasco et al. (2005)
c.9078G>T (p.K2950N) 22 1 Missense U.V. 1405
c.9225G>A (p.L2999L) 23 1 Synonymous Pol. 4527
c.9603C>G (p.L3125L) 25 1 Synonymous Pol. Velasco-Sampedro et al. (2002)
c.9729+143A>T I-25 1 Intronic variant Pol. Velasco-Sampedro et al. (2002)
c.10204A>T (p.K3326X) 27 2 Nonsense Pol. 1179
c.10462A>G (p.I3412V) 27 3 Missense Pol. 1452
c.10338 G>A (p.R3370R) 27 1 Synonymous Pol. 2729
aFrequencies below 0.01 are indicated as number of times the mutation was identiﬁed in this set of patients
bPol Polymorphism, U.V. unclassiﬁed variant
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the mutation c.5272-1G>A, it was found ﬁve times in
our complete cohort of BC patients, but it has also
been detected in one sporadic BC case without known
familial history, who was diagnosed at 54 years of age
(data not shown). This DNA change is relatively rare
in the BIC database (only three records in Western
European and Spanish populations). Therefore, these
data also suggest a putative founder eﬀect in Spain,
which has not been demonstrated yet. Finally, the
third most common mutation of BRCA1 (three unre-
lated families, Table 1) is the splicing mutation
c.330A>G (r.310_331del22) of Galician origin (Vega
et al. 2001), which was detected only once in this
cohort of 309 families.
Frequency of mutations by selection criteria
The distribution of deleterious mutations according to
the selection criteria was 3/67 (4.5%) in group I, 3/33
(9.1%) in group II, 17/62 (27.4%) in group III, 6/27
(22.2%) in group IV, 1/14 in group V, 3/30 (10%) in
group VI, 2/27 (7.4%) in BC patients with unknown
familial history and 4/45 in healthy individuals with
familial antecedents with BC. No mutations were found
in groups VII (two ovarian cancers) and VIII (BC +
familial aggregation). As expected, a great proportion of
mutations were identiﬁed in patients from groups III
and IV (59% of all mutations), as they showed the
highest ratio of cancer-prone mutations (27.4 and
22.2%, respectively). This frequency of mutations by
clinical group is similar to the results previously reported
in the Spanish population (Diez et al. 2003).
Unclassiﬁed variants and polymorphisms
The vast majority of mutations, 77 variants (32 of
BRCA1 and 45 of BRCA2, Table 2), could not be clas-
siﬁed as pathogenic mutations. As previously reported in
other populations (Katagiri et al. 1998), missense vari-
ants outweighed deleterious mutations (34 versus 24).
Fifty-nine DNA changes were considered as mere
polymorphisms, including the two novel variants
c.5294A>G of BRCA1 and c.744+14C>T of BRCA2
(Table 2). The remaining 18 mutations (17 missense
mutations and one intronic variant) were variants of
unknown physiological eﬀect or unclassiﬁed variants,
including the novel missense mutation c.8099A>G
(p.Y2624C), which aﬀected a conserved residue of
BRCA2 (Table 2). Unfortunately, familial segregation
could not be performed as this patient belongs to the
group of young patients without known familial ante-
cedents. Although a great number of the 1,346 diﬀerent
missense mutations (one in four codons of the BRCA
genes has a missense mutation) may presumably be re-
lated to the disease, they should be regarded as unclas-
siﬁed variants since a functional assay of the BRCA
proteins is still not available. Therefore, the role of these
unclassiﬁed missense mutations in BC and OC remains
to be elucidated. Despite a comprehensive analysis of
BRCA1 and BRCA2, there will be high-risk BC families
without deleterious mutations in these genes. In fact, the
cumulative evidence from several studies suggests the
putative inﬂuence of additional moderate or high pene-
trance genes (Nathanson and Weber 2001). Their char-
acterization will contribute to clarifying the spectrum of
genes involved in familial BC.
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